SCL Science Inc

SCL Science Inc has a market price of 1,874 KRW per share and a market capitalization of 63.74 billion KRW, with a price-to-book ratio of 2.61 and a price-to-tangible-book ratio of 2.61. The company's enterprise value to EBITDA is -26.76, indicating a negative earnings multiple, and an enterprise value to revenue of 4.18. The company's liquidity position is characterized by a current ratio of 0.95 and a negative net cash position after subtracting total debt. The company's profitability is negative, with a return on equity of -16.09% and a return on assets of -4.92%. These metrics are below the industry median for Pharmaceuticals, which typically shows positive returns on equity and assets. The company's operating income is -3.43 billion KRW, and its net income is -3.93 billion KRW. The gross profit margin is 19.1%, which is below the industry median for Pharmaceuticals. SCL Science Inc's revenue is concentrated in its core business of medical hemostatic agents and bio-logistics, with no disclosed geographic diversification in the financial snapshot. The company's revenue concentration in a single product line and geographic region increases its exposure to market-specific risks. The company's growth trajectory is negative, with a net income decline of 100% year-over-year and an operating income decline of 100% year-over-year. The company's capital expenditures are -2.43 billion KRW, indicating a reduction in investment in long-term assets. The company's free cash flow is -3.50 billion KRW, reflecting a cash outflow from operations after capital expenditures. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. The company's debt-to-equity ratio is 1.32, indicating a leveraged capital structure. The company's liquidity position is further constrained by a current ratio of 0.95, which is below 1. Recent events include the company's transition from InnoTherapy Inc to SCL Science Inc, reflecting a strategic rebranding. The company's recent financial performance indicates a need for operational improvements to achieve profitability. The company's focus on medical hemostatic agents and bio-logistics suggests a specialized market position.